End-of-day quote
Shanghai S.E.
06:00:00 2024-05-09 pm EDT
|
5-day change
|
1st Jan Change
|
28.74
CNY
|
-3.94%
|
|
-1.17%
|
-44.81%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,992
|
5,156
|
2,846
|
-
|
-
|
Enterprise Value (EV)
1 |
3,992
|
5,156
|
2,846
|
2,846
|
2,846
|
P/E ratio
|
-12.3
x
|
-17.5
x
|
-6.03
x
|
-23.1
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
21.9
x
|
5.84
x
|
2.56
x
|
EV / Revenue
|
-
|
-
|
21.9
x
|
5.84
x
|
2.56
x
|
EV / EBITDA
|
-
|
-17.9
x
|
-6.27
x
|
-8.76
x
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
3.77
x
|
4.27
x
|
8.48
x
|
-
|
Nbr of stocks (in thousands)
|
99,016
|
99,016
|
99,016
|
-
|
-
|
Reference price
2 |
40.32
|
52.07
|
28.74
|
28.74
|
28.74
|
Announcement Date
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
130
|
487
|
1,110
|
EBITDA
1 |
-
|
-287.7
|
-454
|
-325
|
-
|
EBIT
1 |
-
|
-294.4
|
-459
|
-331
|
-
|
Operating Margin
|
-
|
-
|
-353.08%
|
-67.97%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-294.4
|
-459
|
-331
|
-
|
Net income
1 |
-301.5
|
-294.5
|
-472.1
|
-123.5
|
-
|
Net margin
|
-
|
-
|
-363.15%
|
-25.37%
|
-
|
EPS
2 |
-3.270
|
-2.970
|
-4.770
|
-1.245
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-22.3%
|
-20%
|
-66.9%
|
-44%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-18.2%
|
-62.3%
|
-77.2%
|
-
|
Assets
1 |
-
|
1,614
|
757.8
|
160
|
-
|
Book Value Per Share
2 |
-
|
13.80
|
6.730
|
3.390
|
-
|
Cash Flow per Share
2 |
-
|
-2.580
|
-4.880
|
-3.770
|
-
|
Capex
1 |
-
|
99.2
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -44.81% | 394M | | +17.96% | 44.96B | | +1.17% | 42.65B | | +46.56% | 41.85B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|